New Strategies in Academic-Industry Collaborations
Decision Resources
June 11, 2009 26 Pages - SKU: DECR2287675
|
|
Introduction
Major pharmaceutical companies are showing increased interest in directly sponsoring academic
research to access innovation and fill dwindling pipelines. Recent agreements involve higher levels
of collaboration and funding, are broader in scope, and focus on more-basic research than previously.
This increased collaboration among scientists performing basic research, clinical researchers, and
drug developers will accelerate the shift to translational medicine and has the potential to yield great
benefits to patients and society.
Questions Answered in This Report
- Pharmaceutical companies have recently formed numerous collaborations with large research institutions.
What factors are driving this interest? What are the key features of recent collaborative
agreements? How does each organization benefit from these arrangements?
- The environment of academic technology transfer to industry is changing. What impact has the
Bayh-Dole Act had on technology transfer? How do academic institutions manage academicindustry
relationships? Which institutions are leading in innovation and commercialization of
technology?
- Drug developers are experimenting with different approaches to academic-industry relations. Which
key collaborations illustrate these new approaches? What strategic interests of the pharmaceutical
industry do these agreements serve? How will universities and companies measure
success?
- Relationships between academia and industry present special challenges. How do the missions and
goals of academia and industry differ? What confl icts can arise with respect to industry funding
of academic researchers? How can institutions and companies manage these differences?
Scope
- Factors in academic-industry collaborations: historical relationships, dwindling pharmaceutical
pipelines, diminishing federal funding for academia.
- Technology transfer: impact of Bayh-Dole, tech transfer offices, inventions and innovation,
challenges in academic-industry relationships.
- New approaches in academic-industry relationships: close-collaboration, broad-scope,
early-stage research.
- Translational medicine: theme of collaborations, goals, motivations.
- Drug discovery centers: academic centers for dug discovery, industry discovery centers,
pharmaceutical incubators.
- Notable collaborators: AstraZeneca, Centocor, GlaxoSmithKline, Janssen Pharmaceutica,
Merck, Novartis, Pfizer; Columbia University Medical Center, Harvard Medical School,
Harvard Stem Cell Institute, Immune Disease Institute, MIT, University of California, San
Francisco, University of Michigan, Vanderbilt University, Washington University.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction to Academic-Industry Collaborations
- Impact of Bayh-Dole on Technology Transfer to Industry
- Bayh-Dole and the Rise of Technology Transfer Offices
- Academia: A Rich Source of Novel Inventions and Innovation for Drug Discovery
- Challenges in Academic-Industry Relationships
- New Approaches in Academic-Industry Collaborations
- Collaborative Models
- Translational Medicine
- Academic and Industry Centers for Drug Discovery
- Academic Drug Discovery Centers
- Pharmaceutical R&D Centers
- Pharmaceutical R&D Incubators
- Academic-Industry Collaborations of Note
- Merck/Harvard Medical School
- GSK/Harvard Stem Cell Institute
- GSK/Immune Disease Institute
- AstraZeneca/Columbia University Medical Center
- Pfizer/ Washington University
- Pfizer/University of California, San Francisco
- Janssen Pharmaceutica/Vanderbilt University
- Centocor/University of Michigan
- Novartis/MIT
- Outlook for Academic-Industry Collaborations
- Tables
- 1. Select Academic Drug Discovery Centers
- 2. Select Pharmaceutical R&D Centers
- 3. Select Academic-Industry Collaborations
- 4. R&D Expenditures of Top Pharmaceutical Companies, 2008
- Figures
- 1. Annual National Institutes of Health Budget, 2001-2010
- 2. Staffing of U.S. Technology Transfer Offices, 1998-2007
- 3. Relationships Among Academic Research Institutions and External Entities
- 4. Industrial Research Support for U.S. Universities, Hospitals, and Research Institutions
- 5. Top 20 Academic Biotechnology Patent Filers, 2002-2006
Share this report
Other tasks Related Markets Research & Development Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
